PedAM
Pediatric Disease Annotations & Medicines
| dermatitis | ||||
| Disease ID | 1115 |
|---|---|
| Disease | dermatitis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:6) C0002111 | allergy | 28 C0033774 | pruritus | 23 C0037284 | skin lesions | 17 C0426768 | o sign | 3 C0571154 | allergy to gold | 1 C0206141 | hypereosinophilic syndrome | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs199473704 | 17706768 | 162514 | TRPV3 | umls:C0011603 | BeFree | We conclude that the G573S and G573C substitutions render the TRPV3 channel spontaneously active under normal physiological conditions, which in turn alters ion homeostasis and membrane potentials of skin keratinocytes, leading to hair loss and dermatitis-like skin diseases. | 0.002995792 | 2008 | TRPV3 | 17 | 3524224 | C | T,A |
| rs33980500 | 23202271 | 53342 | IL17D | umls:C0011603 | BeFree | In the absence of IL-17 signaling, IL-22 was the main contributor to skin inflammation, which provides a molecular mechanism for the association of Act1(D10N) with psoriasis susceptibility. | 0.001085767 | 2013 | TRAF3IP2;TRAF3IP2-AS1 | 6 | 111592059 | C | T |
| rs33980500 | 23202271 | 50616 | IL22 | umls:C0011603 | BeFree | In the absence of IL-17 signaling, IL-22 was the main contributor to skin inflammation, which provides a molecular mechanism for the association of Act1(D10N) with psoriasis susceptibility. | 0.001900093 | 2013 | TRAF3IP2;TRAF3IP2-AS1 | 6 | 111592059 | C | T |
| rs33980500 | 23202271 | 10758 | TRAF3IP2 | umls:C0011603 | BeFree | In the absence of IL-17 signaling, IL-22 was the main contributor to skin inflammation, which provides a molecular mechanism for the association of Act1(D10N) with psoriasis susceptibility. | 0.000271442 | 2013 | TRAF3IP2;TRAF3IP2-AS1 | 6 | 111592059 | C | T |
| rs61816761 | 21501248 | 2312 | FLG | umls:C0011603 | BeFree | Individuals who are homozygous for the 2282del4 and R501X filaggrin null mutations do not always develop dermatitis and complete long-term remission is possible. | 0.002985861 | 2012 | FLG;FLG-AS1 | 1 | 152313385 | G | A,T |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:16) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0011603 | betamethasone | D001623 | 378-44-9 | dermatitis | MESH:D003872 | therapeutic | 8273557 | ||
| C0011603 | chloroquine | D002738 | 1954/5/7 | dermatitis | MESH:D003872 | therapeutic | 10612109 | ||
| C0011603 | dapsone | D003622 | 80-08-0 | dermatitis | MESH:D003872 | marker/mechanism | 15947852 | ||
| C0011603 | cisplatin | D002945 | 15663-27-1 | dermatitis | MESH:D003872 | marker/mechanism | 16972957 | ||
| C0011603 | fluorouracil | D005472 | 51-21-8 | dermatitis | MESH:D003872 | marker/mechanism | 10099659 | ||
| C0011603 | gefitinib | C419708 | 184475-35-2 | dermatitis | MESH:D003872 | marker/mechanism | 15196742 | ||
| C0011603 | hydroxyurea | D006918 | 127-07-1 | dermatitis | MESH:D003872 | marker/mechanism | 7499134 | ||
| C0011603 | methotrexate | D008727 | 1959/5/2 | dermatitis | MESH:D003872 | marker/mechanism | 10984137 | ||
| C0011603 | nicotine | D009538 | - | dermatitis | MESH:D003872 | marker/mechanism | 9565740 | ||
| C0011603 | pimecrolimus | C117268 | - | dermatitis | MESH:D003872 | marker/mechanism | 12588240 | ||
| C0011603 | quinine | D011803 | 130-95-0 | dermatitis | MESH:D003872 | marker/mechanism | 4229630 | ||
| C0011603 | tacrolimus | D016559 | 109581-93-3 | dermatitis | MESH:D003872 | therapeutic | 11407316 | ||
| C0011603 | ticlopidine | D013988 | 55142-85-3 | dermatitis | MESH:D003872 | marker/mechanism | 9798669 | ||
| C0011603 | tiopronin | D008625 | 1953/2/2 | dermatitis | MESH:D003872 | marker/mechanism | 3084782 | ||
| C0011603 | valproic acid | D014635 | 99-66-1 | dermatitis | MESH:D003872 | marker/mechanism | 8033931 | ||
| C0011603 | vinorelbine | C030852 | 71486-22-1 | dermatitis | MESH:D003872 | marker/mechanism | 15196742 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003872 | elidel | pimecrolimus | 1% | CREAM;TOPICAL | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003872 | 12/13/2001 | elidel | pimecrolimus | Treatment of mild/moderate atopic dermatitis | Indicated for short-term and intermittent long-term therapy for mild to moderate atopic dermatitis in non-immunocompromised patients 2 years and older Not recommended for use in pediatric patients less than 2 years of age. Infants on Elidel Cream had an increased incidence of some adverse events compared to vehicle which included pyrexia, URI, nasopharyngitis, gastroenteritis, otitis media, and diarrhea. | Labeling | B | - | - | - | Novartis | 09/24/2001 | FALSE' |